Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model.
While CpG oligodeoxynucleotides (ODN) are excellent candidates for cancer immunotherapeutics, the numbers of usable CpG ODNs are limited in current clinical settings. To resolve this, we investigated whether novel CpG ODN (KSK-CpG) would be an effective immunotherapeutic in a murine tumor model by affecting in vivo and in vitro parameters, such as survival span, the number of tumor nodules, natural killer (NK) cell and cytotoxic T lymphocyte (CTL) activity and interleukin (IL)-6 or IL-12 cytokine release in splenocytes. We found that KSK-CpG was effective in the murine cancer model by way of prolonging survival span, reducing the number of tumor nodules, augmenting NK cell and CTL cytotoxicity, as well as evoking IL-6 and IL-12 cytokine release in splenocytes. Collectively, these data demonstrate that KSK-CpG is active against the highly malignant B16BL6 and EL4 tumor mouse model via innate immune augmentation.
Cho
Hyeon Cheol
HC
Department of Microbiology, Wonju College of Medicine, Yonsei University, Wonju 220-701, South Korea.
Kim
Bo Hwan
BH
Kim
Kyunghoon
K
Park
Ju Youn
JY
Chang
Jae-Ho
JH
Kim
Soo-Ki
SK
D000818:Animals; D004195:Disease Models, Animal; D007167:Immunotherapy; D007371:Interferon-gamma / Q000276:immunology; D018664:Interleukin-12 / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology; D008546:Melanoma, Experimental / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009369:Neoplasms; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use*; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects* / Q000276:immunology; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D018664:Interleukin-12; D007371:Interferon-gamma